Seres Therapeutics, Inc. MCRB
1.56 USD -0.14 (-8.24%)
At closeNov 11, 2026, 5:44 AM EST
1.68 +0.12 +7.69%
Pre-market · Nov 11, 5:44 AM ET
1.55 Day range 1.74
1.55 52-week range 29.98
- YTD
- -89.52%
- 1 year
- -89.53%
News
zacks.com Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates Seres Therapeutics (MCRB) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to earnings of $0.94 per share a year ago.
benzinga.com Seres Therapeutics Q3 EPS $(1.63) Misses $(1.00) Estimate, Sales $593.000K Miss $6.350M Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.63) per share which missed the analyst consensus estimate of $(1.00) by 63 percent. This is a 273.4 percent decrease over earnings of…
globenewswire.com Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for…
benzinga.com Seres Therapeutics Announces Publication Of Results From Phase 1b Clinical Study Of SER-155 In Adults Undergoing Allogeneic Hematopoietic Cell Transplantation In Nature Medicine Issue Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placeboTranslational data…
benzinga.com On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026 On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and…
benzinga.com Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tubeSER-428 significantly reduced…